hot news

Shaanxi International Medical Exchange Promotion Association (SXIMEA) Liver Tumor MDT Committee's Provincial, the Yulin Station Tour Successfully completed.

On February 25, 2023, the first SXIMEA’s provincial tour of the Liver Tumor MDT Special Committee was successfully held at the Yulin Station. The conference took place offline, with the presence of Professor Qingguang Liu, the honorary chairman of the Liver Tumor MDT Special Committee of the SXIMEA  and Vice President of the First Affiliated Hospital of Xi'an Jiao Tong University; SXIMEA’s Professor Cheng Guo, chairman of the Liver Tumor MDT Special Committee and SXIMEA’s Professor of Hepatobiliary Surgery the First Affiliated Hospital of Xi'an Jiao Tong University; SXIMEA’s Professor Tao Song, Vice Chairman SXIMEA’s Professor Xin Zheng, Standing Committee Member; and Professor Ping Gao, Head of the Hepatobiliary Department of Yulin Second Hospital, among other experts who attended the meeting in person.

The conference began with splendid opening remarks by Professor Qingguang Liu, the Honorary Chairman of the Liver Tumor MDT Special Committee of the SXIMEA and Vice President the First Affiliated Hospital of Xi'an Jiao Tong University, and Professor Ping Gao, Head of the Hepatobiliary Department of Yulin Second Hospital.

The conference continued with Professor Bin Zhang from Yulin First Hospital as the host. First, Associate Professor Xin Zheng from President the First Affiliated Hospital of Xi'an Jiao Tong University, and a standing committee member of the Liver Tumor MDT Special Committee of SXIMEA, presented "Laparoscopic Anatomical Right Hepatectomy," showcasing the treatment methods for liver cancer from a surgical perspective. The liver is the most common site of late-stage colorectal cancer metastasis, with over half of patients eventually developing liver metastasis. So, how should these patients be treated? Associate Professor Tao Song from the First Affiliated Hospital of Xi'an Jiao Tong University, and vice chairman of the Liver Tumor MDT Special Committee of SXIMEA, interpreted the "Progress in Surgery of Liver Metastasis from Colorectal Cancer," elucidating the diagnostic and therapeutic pathway for patients with liver metastasis from colorectal cancer. Finally, SXIMEA’s Professor Cheng Guo from the Hepatobiliary Surgery Department of First Affiliated Hospital of Xi'an Jiao Tong University, and chairman of the Liver Tumor MDT Special Committee of SXIMEA, gave an exciting presentation on "Exploring New Adjuvants for Liver Cancer." SXIMEA’s Professor Cheng Guo stated: China has a high incidence of hepatocellular carcinoma (HCC), accounting for 45.3% of new HCC cases globally and 47.1% of global deaths. Liver tumors (including primary liver cancer and metastatic liver cancer) are significant diseases threatening human health, and there are still many challenging breakthrough points. Early-stage patients who undergo radical surgery can have a survival rate of over five years, while middle and late-stage patients can have a five-year survival rate of over 50% after conversion resection. The era of exploring new adjuvants for borderline resectable liver cancer has arrived. The treatment of liver cancer in the new era is a new era of target-immune treatment centered on surgery! Under the host Professor Xiong Wang from Jingbian People's Hospital, there were splendid discussions by Professor Bingxin Jia from Yulin Northern Hospital, Professor Yefei Wang from Yulin First Hospital, and others. They expressed that the treatment of liver cancer in the new era should be centered on surgery and cannot be separated from the strategic deployment of targeted immune treatment.

The second part of the conference was hosted by Professor Dongli Zhao from the First Affiliated Hospital of Xi'an Jiao Tong University. First, Professor Yuelang Zhang from the same hospital presented "Imaging Diagnosis of Intrahepatic Cholangiocarcinoma," where Professor Zhang analysed the complete diagnostic process of intrahepatic cholangiocarcinoma from an imaging perspective. Next, SXIMEA’s Professor Min Jiao from the First Affiliated Hospital of Xi'an Jiao Tong University shared "Conversion Therapy Brings New Hope." Finally, attending physician Xutian Wang from the same hospital presented an intriguing case of liver cancer, sharing the complete treatment process for liver cancer patients from a practical standpoint. Under the moderation of Professor Mingrui Xie from Yulin Second Hospital, Professor Xiaojing Liu from the First Affiliated Hospital of Xi'an Jiao Tong University, Professor Cairong Wang from Jingbian People's Hospital and others had an in-depth exchange and discussion on the above topics and cases. They expressed that standardized treatment of liver tumors requires multidisciplinary collaboration to benefit patients together.

The conference concluded with a summary by Professor Qingguang Liu, Honorary Chairman of the XIMEA Liver Cancer MDT Special Committee and Deputy Dean of the First Affiliated Hospital of Xi'an Jiao Tong University. Professor Liu stated: The Liver Cancer MDT Special Committee of the XIMEA and the Liver Cancer MDT of the First Affiliated Hospital of Xi'an Jiao Tong University will actively build an academic exchange platform to learn from each other and make progress together. We aim to make positive contributions to the advancement of the industry, provide high-quality, efficient, and safe one-stop, standardized liver cancer medical services to the public, and he congratulated on the successful conclusion of this Yulin Station tour.